405 related articles for article (PubMed ID: 31413145)
1. MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.
Vilgelm AE; Saleh N; Shattuck-Brandt R; Riemenschneider K; Slesur L; Chen SC; Johnson CA; Yang J; Blevins A; Yan C; Johnson DB; Al-Rohil RN; Halilovic E; Kauffmann RM; Kelley M; Ayers GD; Richmond A
Sci Transl Med; 2019 Aug; 11(505):. PubMed ID: 31413145
[TBL] [Abstract][Full Text] [Related]
2. Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2.
Pack LR; Daigh LH; Chung M; Meyer T
Nat Commun; 2021 Jun; 12(1):3356. PubMed ID: 34099663
[TBL] [Abstract][Full Text] [Related]
3. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
[TBL] [Abstract][Full Text] [Related]
6. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
[TBL] [Abstract][Full Text] [Related]
7. Human epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex: IMPLICATION OF A NOVEL MDMX SER-314 PHOSPHOSITE.
Gerarduzzi C; de Polo A; Liu XS; El Kharbili M; Little JB; Yuan ZM
J Biol Chem; 2016 Dec; 291(50):25937-25949. PubMed ID: 27777309
[TBL] [Abstract][Full Text] [Related]
8. MDM2 Antagonists Counteract Drug-Induced DNA Damage.
Vilgelm AE; Cobb P; Malikayil K; Flaherty D; Andrew Johnson C; Raman D; Saleh N; Higgins B; Vara BA; Johnston JN; Johnson DB; Kelley MC; Chen SC; Ayers GD; Richmond A
EBioMedicine; 2017 Oct; 24():43-55. PubMed ID: 29030058
[TBL] [Abstract][Full Text] [Related]
9. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ
Nat Commun; 2021 Aug; 12(1):5112. PubMed ID: 34433817
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
Prall OW; Sarcevic B; Musgrove EA; Watts CK; Sutherland RL
J Biol Chem; 1997 Apr; 272(16):10882-94. PubMed ID: 9099745
[TBL] [Abstract][Full Text] [Related]
11. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Choi HJ; Chung TW; Kang SK; Lee YC; Ko JH; Kim JG; Kim CH
Glycobiology; 2006 Jul; 16(7):573-83. PubMed ID: 16574813
[TBL] [Abstract][Full Text] [Related]
12. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
13. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
[TBL] [Abstract][Full Text] [Related]
14. Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib.
Ji W; Shi Y; Wang X; He W; Tang L; Tian S; Jiang H; Shu Y; Guan X
Int J Biol Sci; 2019; 15(3):522-532. PubMed ID: 30745839
[TBL] [Abstract][Full Text] [Related]
15. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
17. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S
Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512
[TBL] [Abstract][Full Text] [Related]
18. CDK4 inhibition diminishes p53 activation by MDM2 antagonists.
Sriraman A; Dickmanns A; Najafova Z; Johnsen SA; Dobbelstein M
Cell Death Dis; 2018 Sep; 9(9):918. PubMed ID: 30206211
[TBL] [Abstract][Full Text] [Related]
19. Activation of cyclin D1-kinase in murine fibroblasts lacking both p21(Cip1) and p27(Kip1).
Sugimoto M; Martin N; Wilks DP; Tamai K; Huot TJ; Pantoja C; Okumura K; Serrano M; Hara E
Oncogene; 2002 Nov; 21(53):8067-74. PubMed ID: 12444543
[TBL] [Abstract][Full Text] [Related]
20. Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver.
Albrecht JH; Poon RY; Ahonen CL; Rieland BM; Deng C; Crary GS
Oncogene; 1998 Apr; 16(16):2141-50. PubMed ID: 9572495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
